Nabriva Therapeutics plc is a clinical‐stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel anti‐infective agents. The company’s research efforts focus on addressing critical unmet needs in the treatment of serious bacterial infections, with a particular emphasis on combating antimicrobial resistance. Since its founding in 2006, Nabriva has built a portfolio of antibiotic candidates designed to offer new therapeutic options for patients suffering from community‐acquired and hospital‐acquired infections.
The company’s lead product, lefamulin, is a first‐in‐class pleuromutilin antibiotic that received U.S. Food and Drug Administration approval in 2019 under the brand name Xenleta for the treatment of community‐acquired bacterial pneumonia in adults. In Europe, lefamulin is marketed as Xenleta and Xydella under a marketing authorization granted by the European Medicines Agency. Beyond its approved indication, Nabriva continues to explore the potential of pleuromutilin antibiotics in clinical development programs targeting other serious infections, including hospital‐acquired bacterial pneumonia and pathogens resistant to existing drug classes.
Nabriva maintains a global footprint, serving markets in the United States and Europe. The company is headquartered in Dublin, Ireland, with additional research and development sites in King of Prussia, Pennsylvania, and Vienna, Austria. This international presence supports Nabriva’s efforts to collaborate with regulatory authorities and commercial partners worldwide.
The company’s leadership team brings together seasoned professionals with expertise in infectious disease research, clinical development, regulatory strategy and commercial execution. Guided by its mission to advance new antibiotic treatments, Nabriva remains focused on delivering innovative solutions to healthcare providers and patients confronting the growing challenge of antibiotic resistance.
AI Generated. May Contain Errors.
